Dr Reddy’s Laboratories has launched Metoprolol Succinate ER (Extended-Release) tablets (25mg, 50mg, 100mg and 200mg), a bioequivalent generic version of Toprol-XL (Metoprolol Succinate) tablets in the US market on September 11, 2012.
Metoprolol Succinate ER tablets (25mg, 50mg, 100mg and 200mg) were approved by the United States Food and Drug Administration (US FDA) in August 2012.
The Toprol-XL brand and generic had US sales of about $1.13 billion for the most recent twelve months ending June 2012. The company’s Metoprolol Succinate ER tablets 25mg, 50mg, 100mg and 200mg are available in bottle counts of 100 and 500.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1845.90 |
| Dr. Reddys Lab | 1270.10 |
| Cipla | 1292.00 |
| Zydus Lifesciences | 930.75 |
| Lupin | 2246.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: